OVID News and Press, Ovid Therapeutics Inc. From 08/27/20

Altimmune provides positive updates for AdCOVID Altimmune Inc. ( ALT ) reported positive data from the preclinical studies of its lead vaccine candidate, AdCOVID. The company is carrying out these studies as part of its collaboration with the University of Alabama at Birmingham for dev...

Ovid Therapeutics (NASDAQ: OVID ) has priced its public offering of 6.25M common shares at $8 per share yielding gross proceeds of $50M. Closing date is August 27. More news on: Ovid Therapeutics Inc., Healthcare stocks news, , Stocks on the move, Read more ...

Urban One (NASDAQ: UONE ) +85% . More news on: Urban One, Inc., Ovid Therapeutics Inc., RealNetworks, Inc., Stocks on the move, , Read more ...

Ovid Therapeutics (NASDAQ: OVID ) and development partner Takeda Pharmaceutical Company (NYSE: TAK ) announce positive results from a Phase 2 clinical trial, ELEKTRA , evaluating soticlestat in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), rare, treatment-resist...

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of an underwritten offering (the “Offerin...

Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome study population    Statistically significant reduction in seizure f...

Ovid Therapeutics (NASDAQ: OVID ) : Q2 GAAP EPS of -$0.41 misses by $0.05 . More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020 Multiple data readouts for soticlestat expected in Q3 2020, including from the randomized Phase 2 ELEKTRA trial in Dravet syndrome and Lennox-Gast...

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical ...

At $6.75/share, Ovid Therapeutics Inc. ( OVID ) has a fully diluted market cap of ~$430MM. After recent receipt of $20MM as an upfront payment from a new commercial partner, OVID has an approximate cash balance of $50MM. With $0 debt, OVID's enterprise valuation is therefore approximately $380...